Research Analysts’ Recent Ratings Changes for Evolent Health (EVH)

Several brokerages have updated their recommendations and price targets on shares of Evolent Health (NYSE: EVH) in the last few weeks:

• 1/23/2025 – Evolent Health had its price target lowered by analysts at Canaccord Genuity Group Inc. from $23.00 to $16.00. They now have a “buy” rating on the stock.
• 1/22/2025 – Evolent Health had its price target lowered by analysts at Truist Financial Co. from $20.00 to $15.00. They now have a “buy” rating on the stock.
• 1/21/2025 – Evolent Health had its price target lowered by analysts at Stephens from $16.00 to $12.00. They now have an “equal weight” rating on the stock.
• 1/16/2025 – Evolent Health had its price target lowered by analysts at UBS Group AG from $27.00 to $14.00. They now have a “buy” rating on the stock.
• 1/14/2025 – Evolent Health had its price target lowered by analysts at Royal Bank of Canada from $20.00 to $17.00. They now have an “outperform” rating on the stock.
• 1/13/2025 – Evolent Health had its price target lowered by analysts at Truist Financial Co. from $24.00 to $20.00. They now have a “buy” rating on the stock.
• 1/10/2025 – Evolent Health had its price target lowered by analysts at JMP Securities from $27.00 to $18.00. They now have a “market outperform” rating on the stock.
• 1/10/2025 – Evolent Health had its price target lowered by analysts at Citigroup Inc. from $21.00 to $18.00. They now have a “buy” rating on the stock.
• 1/10/2025 – Evolent Health is now covered by analysts at Needham & Company LLC. They set a “buy” rating and a $15.00 price target on the stock.
• 12/3/2024 – Evolent Health had its price target lowered by analysts at BTIG Research from $36.00 to $29.00. They now have a “buy” rating on the stock.

Evolent Health Stock Performance

NYSE:EVH opened at $10.16 on Friday. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.58. Evolent Health, Inc. has a twelve month low of $9.74 and a twelve month high of $35.00. The company has a market capitalization of $1.18 billion, a P/E ratio of -11.16 and a beta of 1.45. The firm has a 50-day moving average price of $11.50 and a two-hundred day moving average price of $20.44.

Evolent Health (NYSE:EVH) last released its earnings results on Thursday, November 7th. The technology company reported ($0.08) EPS for the quarter, missing the consensus estimate of $0.30 by ($0.38). Evolent Health had a negative net margin of 2.93% and a positive return on equity of 6.30%. The business had revenue of $621.40 million during the quarter, compared to analyst estimates of $625.58 million. During the same quarter in the previous year, the company posted $0.19 earnings per share. As a group, research analysts expect that Evolent Health, Inc. will post 0.26 earnings per share for the current fiscal year.

Institutional Trading of Evolent Health

Large investors have recently modified their holdings of the business. Covestor Ltd lifted its position in shares of Evolent Health by 138.1% during the third quarter. Covestor Ltd now owns 1,424 shares of the technology company’s stock worth $40,000 after purchasing an additional 826 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Evolent Health by 5,365.5% during the third quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company’s stock worth $45,000 after purchasing an additional 1,556 shares during the period. Quarry LP acquired a new stake in Evolent Health during the second quarter worth about $32,000. Creative Planning lifted its holdings in Evolent Health by 12.2% in the second quarter. Creative Planning now owns 18,091 shares of the technology company’s stock worth $346,000 after acquiring an additional 1,973 shares during the last quarter. Finally, R Squared Ltd acquired a new position in Evolent Health during the 4th quarter valued at approximately $31,000.

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.